BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2876498)

  • 1. Acute and long-term effects of SMS 201-995 in acromegaly.
    Lamberts SW; del Pozo E
    Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of acromegaly with sandostatin.
    Tolis G
    Horm Res; 1988; 29(2-3):112-4. PubMed ID: 2900189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
    Lamberts SW; Uitterlinden P; Verschoor L; van Dongen KJ; del Pozo E
    N Engl J Med; 1985 Dec; 313(25):1576-80. PubMed ID: 2866445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Sandler LM; Burrin JM; Williams G; Joplin GF; Carr DH; Bloom SR
    Clin Endocrinol (Oxf); 1987 Jan; 26(1):85-95. PubMed ID: 2879656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
    Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
    Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analog treatment of acromegaly: new aspects.
    Lamberts SW; del Pozo E
    Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
    Lamberts SW; Oosterom R; Neufeld M; del Pozo E
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
    Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
    Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations.
    Spinas GA; Zapf J; Landolt AM; Stuckmann G; Froesch ER
    Acta Endocrinol (Copenh); 1987 Feb; 114(2):249-56. PubMed ID: 2881419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.